^
Association details:
| Biomarker: | CD74-ROS1 fusion + MET D1228N + MET amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
Published date:
09/30/2020
Excerpt:
...a patient with metastatic lung adenocarcinoma with CD74‐ROS1 fusion who initially responded to crizotinib and then developed resistance by the acquired mutation of D1228N in the MET kinase domain...Pathological examination revealed poorly differentiated cancer, whereas the NGS‐based 450‐gene panel analysis revealed an additional MET amplification...The patient succumbed to the disease...
DOI:
10.1002/onco.13545
